JPH07508267A - B型肝炎表面抗原および他の抗原からなる複合ワクチン - Google Patents
B型肝炎表面抗原および他の抗原からなる複合ワクチンInfo
- Publication number
- JPH07508267A JPH07508267A JP6500162A JP50016294A JPH07508267A JP H07508267 A JPH07508267 A JP H07508267A JP 6500162 A JP6500162 A JP 6500162A JP 50016294 A JP50016294 A JP 50016294A JP H07508267 A JPH07508267 A JP H07508267A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- hbsag
- adsorbed
- hepatitis
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (31)
- 1.nの値が1またはそれ以上であって、HBsAgを吸着すりための用いられ るアジュバントが水酸化アルミニウムでない、1種またはそれ以上のアルミニウ ム塩からなるアジュバントと混合されたB型肝炎表面抗原(HBsAg)および n個の他の抗原からなる混合ワクチン組成物(ただし、nが1である場合には、 他の抗原はA型肝炎に対する抗原ではない)。
- 2.HBsAgがリン酸アルミニウムに吸着している請求項1記載のワクチン組 成物。
- 3.少なくとも1種の他の抗原がリン酸アルミニウムに吸着している請求項2記 載のワクチン組成物。
- 4.少なくとも1種の他の抗原が水酸化アルミニウムに吸着している請求項2記 載のワクチン組成物。
- 5.nが2、3、4、5または6である上記請求項のいずれかに記載のワクチン 組成物。
- 6.水酸化アルミニウムまたはリン酸アルミニウムに吸着している抗原が、ジフ テリア(D)、破傷風(T)、百日ぜき(P)、不活性化ポリオ(IPV)、ヘ モフィルス・インフルエンザ(Haemophilus influenzae )b(Hib)およびA型肝炎(AH)に対する免疫性を提供する抗原から選択 される請求項5記載の混合ワクチン組成物。
- 7.2種より多い疾患の予防に指向された、HBsAgおよび少なくとも2種の 他の抗原からなる安定かつ有効な混合ワクチン組成物。
- 8.HBsAgがリン酸アルミニウムに吸着している請求項7記載のワクチン組 成物。
- 9.HBsAg以外の少なくとも1種の抗原が水酸化アルミニウムに吸着してい る請求項8記載のワクチン組成物。
- 10.ジフテリアー破傷風−百日ぜき(DTP)−B型肝炎;またはジフテリア −破傷風(DT)−B型肝炎;またはDTP−IPV(不活性化ポリオワクチン )−B型肝炎である請求項7ないし9のいずれか1つに記載の混合ワクチン組成 物。
- 11.ワクチンの安定性が、HBsAg成分の免疫性の実質的な操失なしにワク チンを37℃で1週間保つことのできるものである上記請求項のいずれかに記載 の混合ワクチン組成物。
- 12.適切なワクチン接種計画において1ヵ月間隔でワクチン投与コースを行っ た場合、混合ワクチン中のHBsAgの免疫性が、ヒト・幼児における3回目の 接種の1ヵ月後において200ミリIU/mlまたはそれより大きい幾何平均力 価が見い出されるものであることを特徴とする上記請求項のいずれかに記載の混 合ワクチン組成物。
- 13.A型肝炎に対して防御的である抗原成分からなる上記請求項のいずれかに 記載の混合ワクチン組成物。
- 14.百日ぜき成分からなる上記請求項のいずれかに記載の混合ワクチン組成物 。
- 15.百日ぜき成分が、部分精製もしくは高度に精製された抗原を含有する全細 胞性百日ぜきワクチンまたは無細胞性百日ぜきワクチンである請求項14記載の 混合ワクチン。
- 16.HBsAgおよび安定化アジュバントからなり、HBsAg成分の免疫性 の実質的な損失なしにワクチンを37℃で1週間保つことができるように安定化 アジュバントが選択される多価ワクチン組成物。
- 17.適切なワクチン接種計画において1ヵ月間隔でワクチン投与コースを行っ た場合、混合ワクチン中のHBsAgの免疫性が、ヒト・幼児における3回目の 接種の1ヵ月後において200ミリIU/mlまたはそれより大きい幾何平均力 価を提供することをさらに特徴とする請求項16記載の多価ワクチン組成物。
- 18.アジュバントが1種またはそれ以上のアルミニウム塩から選択される請求 項16または17に記載の多価ワクチン(ただし、HBsAg成分は水酸化アル ミニウムに吸着していない)。
- 19.HBsAgがリン酸アルミニウムに吸着している請求項18記載の多価ワ クチン。
- 20.抗原がワクチン製剤中に存在し、HBsAg以外は水酸化アルミニウムに 吸着している請求項18または19記載の多価ワクチン。
- 21.ジフテリアー破傷風−百日ぜき(無細胞性)−HBsAgである請求項2 0記載のワクチン製剤。
- 22.抗原がワクチン製剤中に存在し、HBsAg以外はリン酸アルミニウムに 吸着している請求項18または19記載の多価ワクチン製剤。
- 23.ジフテリアー破暢風−百日ぜき(全細胞性)−HBsAgである請求項2 2記載のワクチン組成物。
- 24.医薬用途の請求項1ないし23のいずれか1つに記載の組成物。
- 25.B型肝炎ウイルス感染予防のための請求項1ないし23のいずれか1つに 記載の混合ワクチンの製造におけるHBsAgの使用。
- 26.HBsAgがAPに吸着している請求項1ないし23に記載の混合ワクチ ン組成物の製造方法であって、リン酸アルミニウムに吸着しているHBsAgを 1種またはそれ以上の水酸化アルミニウムまたはリン酸アルミニウムに吸着して いる抗原と混合することを特徴とする製造方法。
- 27.HBsAgおよび少なくとも1種の他の抗原からなる安定かつ有効な混合 ワクチンを製剤することを目的とし、それによりHBsAg成分の安定性および /または免疫原性がHBsAgが水酸化アルミニウムに吸着している混合ワクチ ン中におけるよりも高いことを特徴とする、HBsAgを吸着するためのアジュ バントとしてのリン酸アルミニウムの使用。
- 28.ワクチンの安定性が、HBsAg成分の免疫性の実質的な損失なしにワク チンを37℃で1週間保つことができるものである請求項27記載の使用。
- 29.混合ワクチン中のHBsAgの免疫原性が、適切なワクチン接種計画にお いて1ヵ月間隔でワクチン投与コースを行った場合、混合ワクチン中のHBsA gの免疫性が、ヒト・幼児における3回目の接種の1ヵ月後において200ミリ IU/mlまたはそれより大きい幾何平均力価を提供するものである請求項27 記載の使用。
- 30.少なくとも2種の他の抗原が混合物ワクチン中に存在する請求項27ない し29のいずれか1つの記載の使用。
- 31.ヒトにおけるB型肝炎を予防する方法であって、予防が必要なヒト対象を 請求項1ないし23のいずれか1つに記載の有効量のワクチンで処理することか らなる方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929211081A GB9211081D0 (en) | 1992-05-23 | 1992-05-23 | Vaccines |
GB9211081.6 | 1992-05-23 | ||
GB9213308.1 | 1992-06-23 | ||
GB929213308A GB9213308D0 (en) | 1992-06-23 | 1992-06-23 | Vaccine |
PCT/EP1993/001276 WO1993024148A1 (en) | 1992-05-23 | 1993-05-15 | Combined vaccines comprising hepatitis b surface antigen and other antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07508267A true JPH07508267A (ja) | 1995-09-14 |
JP3626996B2 JP3626996B2 (ja) | 2005-03-09 |
Family
ID=26300928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50016294A Expired - Lifetime JP3626996B2 (ja) | 1992-05-23 | 1993-05-15 | B型肝炎表面抗原および他の抗原からなる複合ワクチン |
Country Status (31)
Country | Link |
---|---|
US (1) | US6013264A (ja) |
EP (4) | EP0835663B1 (ja) |
JP (1) | JP3626996B2 (ja) |
KR (1) | KR100287083B1 (ja) |
CN (2) | CN1313152C (ja) |
AP (1) | AP567A (ja) |
AT (2) | ATE444079T1 (ja) |
AU (5) | AU4315693A (ja) |
CA (1) | CA2136429C (ja) |
CY (1) | CY2614B2 (ja) |
CZ (1) | CZ283910B6 (ja) |
DE (4) | DE69319728T2 (ja) |
DK (2) | DK0642355T3 (ja) |
ES (2) | ES2118963T3 (ja) |
FI (1) | FI945483A (ja) |
HK (2) | HK1011290A1 (ja) |
HU (1) | HU220236B (ja) |
IL (1) | IL105770A (ja) |
LU (2) | LU91659I2 (ja) |
MA (1) | MA22894A1 (ja) |
MX (1) | MX9302982A (ja) |
MY (1) | MY110665A (ja) |
NO (1) | NO309675B1 (ja) |
NZ (1) | NZ253065A (ja) |
PT (1) | PT835663E (ja) |
RU (1) | RU2160120C2 (ja) |
SG (1) | SG48365A1 (ja) |
SI (1) | SI9300271A (ja) |
SK (1) | SK280702B6 (ja) |
UA (1) | UA40596C2 (ja) |
WO (1) | WO1993024148A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506045A (ja) * | 1998-03-09 | 2002-02-26 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 併合ワクチン組成物 |
JP2002513771A (ja) * | 1998-05-01 | 2002-05-14 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
JP2008533125A (ja) * | 2005-03-17 | 2008-08-21 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 全細胞百日咳抗原を含む混合ワクチン |
JP2012236864A (ja) * | 2006-08-16 | 2012-12-06 | Novartis Ag | 低減された抗原用量を有するブースターワクチンの製造 |
JP2014028863A (ja) * | 1999-11-29 | 2014-02-13 | Novartis Vaccines & Diagnostics Srl | 血清型BおよびC由来のNeisseriameningitidis抗原、ならびにさらなる抗原を含む組成物 |
JP2015504085A (ja) * | 2012-01-17 | 2015-02-05 | サノフィ・パスツールSanofipasteur | 水酸化酸化アルミニウムへ吸着可能な少なくとも2種類の抗原を含有するワクチンの調製方法 |
WO2022224966A1 (ja) * | 2021-04-20 | 2022-10-27 | Kmバイオロジクス株式会社 | 6種混合液状ワクチン組成物 |
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
CA2222455C (en) | 1995-03-22 | 2013-05-28 | Smithkline Beecham Biologicals S.A. | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
US6696065B1 (en) | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
FR2734484B1 (fr) * | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
US20020054884A1 (en) | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
EP1762246A1 (en) * | 1996-07-02 | 2007-03-14 | Sanofi Pasteur Limited | Multivalent DTP-Polio vaccines |
GB9623233D0 (en) | 1996-11-07 | 1997-01-08 | Smithkline Beecham Biolog | Vaccine composition |
US20010014331A1 (en) | 1996-11-07 | 2001-08-16 | Smithkline Beecham Biologicals S.A. | Acellular pertussis vaccine with diphthriae-and tetanus-toxoids |
CU22629A1 (es) * | 1997-03-06 | 2000-12-22 | Ct Ingenieria Genetica Biotech | Formulaciones inmunopotenciadoras para uso vacunal |
EP0980257A1 (en) * | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
CA2303105A1 (en) * | 1997-09-15 | 1999-03-25 | Pasteur Merieux Msd | Multivalent vaccines |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
US20030049268A1 (en) | 1998-05-01 | 2003-03-13 | Smithkline Beecham Biologicals S.A. | Novel composition |
RU2130778C1 (ru) * | 1998-07-31 | 1999-05-27 | Акционерное общество закрытого типа НПК "Комбиотех Лтд" | Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша |
RU2130779C1 (ru) * | 1998-07-31 | 1999-05-27 | Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" | Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии |
AT408615B (de) * | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
CN1053590C (zh) * | 1998-10-19 | 2000-06-21 | ***长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
CU22871A1 (es) * | 1998-12-02 | 2003-10-21 | Ct Ingenieria Genetica Biotech | Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal |
US6974581B1 (en) * | 1998-12-15 | 2005-12-13 | Aventis Pasteur Limited | Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease |
US7098309B2 (en) * | 1998-12-23 | 2006-08-29 | Merck & Co., Inc. | Recombinant hepatitis B surface antigen |
US7172762B1 (en) * | 1999-01-29 | 2007-02-06 | Pfizer Inc. | Erysipelothrix rhusiopathiae antigens and vaccine compositions |
GB9923060D0 (en) | 1999-09-29 | 1999-12-01 | Chiron Spa | Vaccine |
KR100374813B1 (ko) * | 2000-04-07 | 2003-03-03 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법 |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
PT1296715E (pt) * | 2000-06-29 | 2012-01-19 | Smithkline Beecham Biolog | Composição vacinal multivalente |
KR100385711B1 (ko) * | 2000-07-05 | 2003-05-27 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드와 백일해균 및b형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법 |
KR100401423B1 (ko) * | 2001-01-10 | 2003-10-17 | 주식회사 엘지생명과학 | 혼합 백신의 제조 방법 |
EA006947B1 (ru) | 2001-01-23 | 2006-06-30 | Авентис Пастер | Поливалентная менингококковая полисахаридно-белковая конъюгированная вакцина |
AU2007200116A1 (en) * | 2001-04-03 | 2007-02-01 | Glaxosmithkline Biologicals S.A. | Vaccine composition |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
RU2323002C2 (ru) * | 2001-07-26 | 2008-04-27 | Чирон Срл. | Вакцины, содержащие алюминиевые адъюванты и гистидин |
IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
CU23031A1 (es) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes |
IL164256A0 (en) * | 2002-03-28 | 2005-12-18 | Brenntag Biosector As | Combined dna/protein compositions |
GB0223355D0 (en) * | 2002-10-08 | 2002-11-13 | Chiron Spa | Vaccine |
ES2649048T3 (es) | 2002-11-01 | 2018-01-09 | Glaxosmithkline Biologicals S.A. | Procedimiento de secado |
WO2004067030A2 (en) | 2003-01-30 | 2004-08-12 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
ATE506963T1 (de) | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
AU2005249571B9 (en) | 2004-06-04 | 2011-01-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
WO2006113528A2 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
KR101408113B1 (ko) | 2005-06-27 | 2014-06-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 제조 방법 |
GB0517719D0 (en) * | 2005-08-31 | 2005-10-05 | Chiron Srl | Vaccines containing pili |
BRPI0615420A2 (pt) | 2005-09-01 | 2011-05-17 | Novartis Vaccines & Diagnostic | vacinação múltipla que inclui meningococo do sorogrupo c |
GB0522765D0 (en) * | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
EP1862176A1 (de) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
EP1862177A1 (de) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Ein Verfahren zur Herstellung einer Impfzusammensetzung |
GB0616226D0 (en) * | 2006-08-15 | 2006-09-27 | Novartis Ag | Processes |
GB0617602D0 (en) * | 2006-09-07 | 2006-10-18 | Glaxosmithkline Biolog Sa | Vaccine |
AU2007293673B2 (en) | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
CN101605808A (zh) * | 2007-02-07 | 2009-12-16 | 希格马托制药工业公司 | 人巨细胞病毒(hcmv)的重组抗原 |
EP2142211A1 (en) | 2007-05-02 | 2010-01-13 | GlaxoSmithKline Biologicals S.A. | Vaccine |
PE20100366A1 (es) | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
PE20100365A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
CN102802662A (zh) | 2010-03-18 | 2012-11-28 | 诺华有限公司 | 用于脑膜炎球菌血清组b的含佐剂疫苗 |
FR2966044B1 (fr) * | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
EP2646459B1 (en) | 2010-12-02 | 2020-01-08 | Bionor Immuno AS | Peptide scaffold design |
CN103442730B (zh) | 2011-01-05 | 2016-08-17 | 巴拉特生物技术国际有限公司 | 组合七价疫苗 |
CN103347892B (zh) | 2011-01-06 | 2016-11-02 | 比奥诺尔免疫有限公司 | 单体和多聚体免疫原性肽 |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
BR112013029024A2 (pt) * | 2011-05-11 | 2017-10-31 | Riesbeck Healthcare Sweden Ab | proteína f - uma nova adesina de haemophilus influenzae com propriedades de ligação à laminina e vitronectina |
US20140234360A1 (en) | 2011-09-30 | 2014-08-21 | The United States of America, as represented by the Secretary, Dept.of Health and Human Services | Influenza vaccine |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
ES2653261T3 (es) | 2012-02-01 | 2018-02-06 | Glaxosmithkline Biologicals S.A. | Procedimiento de fermentación |
CN104159603A (zh) * | 2012-03-08 | 2014-11-19 | 诺华股份有限公司 | 带有tlr4激动剂的联合疫苗 |
EP2859011B1 (en) | 2012-06-06 | 2019-12-11 | Bionor Immuno AS | Peptides derived from viral proteins for use as immunogens and dosage reactants |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
BR112015008040A2 (pt) | 2012-10-12 | 2017-07-04 | Glaxosmithkline Biologicals Sa | composição de vacina, vacina de combinação, e, processos para preparar um componente ap e para a fabricação de uma composição de vacina |
DK2863943T3 (en) | 2013-03-08 | 2016-11-07 | Janssen Vaccines & Prevention Bv | acellular pertussis vaccines |
US9993534B2 (en) | 2013-03-12 | 2018-06-12 | Wisconsin Alumni Research Foundation | Method of treating fungal infection |
KR20160040290A (ko) | 2013-08-05 | 2016-04-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 조합 면역원성 조성물 |
AR101256A1 (es) | 2014-07-21 | 2016-12-07 | Sanofi Pasteur | Composición vacunal que comprende ipv y ciclodextrinas |
MA52400B1 (fr) * | 2015-09-16 | 2023-01-31 | Lg Chemical Ltd | Composition de vaccin combinée pour administration multiple |
US11602559B2 (en) | 2016-10-03 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV-1 Env fusion peptide immunogens and their use |
WO2018081832A1 (en) | 2016-10-31 | 2018-05-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptide fragments from filoviruses and their uses |
US11235056B2 (en) | 2017-03-24 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Glycan-masked engineered outer domains of HIV-1 gp120 and their use |
CN111032078A (zh) | 2017-07-18 | 2020-04-17 | 血清研究所印度私人有限公司 | 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法 |
US11136356B2 (en) | 2017-10-16 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
WO2020043874A1 (en) | 2018-08-31 | 2020-03-05 | Glaxosmithkline Biologicals Sa | Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle |
US20210353740A1 (en) | 2018-09-23 | 2021-11-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
AU2019368218A1 (en) | 2018-10-22 | 2021-05-27 | New York University | Recombinant GP120 protein with V1-loop deletion |
WO2020236973A1 (en) | 2019-05-20 | 2020-11-26 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
EP4380613A1 (en) | 2021-08-03 | 2024-06-12 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
WO2023192835A1 (en) | 2022-03-27 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Base-covered hiv-1 envelope ectodomains and their use |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6013718A (ja) * | 1983-07-05 | 1985-01-24 | Chemo Sero Therapeut Res Inst | B型肝炎ワクチン |
JPS60193925A (ja) * | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
US4624918A (en) * | 1984-07-09 | 1986-11-25 | Genentech, Inc. | Purification process for hepatitis surface antigen and product thereof |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4895800A (en) | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
EP0278940A3 (en) | 1987-01-30 | 1988-12-07 | Smithkline Biologicals S.A. | Hepatitis b virus surface antigens and hybrid antigens containing them |
EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
EP0299108B1 (en) | 1987-07-17 | 1994-05-18 | Rhein Biotech Gesellschaft für biotechnologische Prozesse und Produkte mbH | DNA-molecules coding for FMDH control regions and structured gene for a protein having FMDH-activity and their uses |
JPH085804B2 (ja) * | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | A型及びb型肝炎混合アジュバントワクチン |
EP0414374B1 (en) | 1989-07-25 | 1997-10-08 | Smithkline Biologicals S.A. | Novel antigens and methods for their preparation |
CY1934A (en) | 1989-11-06 | 1990-11-01 | Smithkline Beecham Biolog | Process |
DE69113991T2 (de) | 1990-02-12 | 1996-03-21 | Smithkline Beecham Biologicals S.A., Rixensart | Impfstoff. |
GB9007024D0 (en) | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
WO1992011291A1 (en) * | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
CA2067003A1 (en) | 1991-04-29 | 1992-10-30 | Peter J. Kniskern | Hbsag escape mutant vaccine |
AU657168B2 (en) * | 1991-09-18 | 1995-03-02 | Amgen, Inc. | Hepatitis B vaccine with bile salt adjuvant |
HU219056B (hu) * | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
CA2222455C (en) | 1995-03-22 | 2013-05-28 | Smithkline Beecham Biologicals S.A. | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
RU2130778C1 (ru) | 1998-07-31 | 1999-05-27 | Акционерное общество закрытого типа НПК "Комбиотех Лтд" | Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша |
KR100385711B1 (ko) | 2000-07-05 | 2003-05-27 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드와 백일해균 및b형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법 |
KR100401423B1 (ko) | 2001-01-10 | 2003-10-17 | 주식회사 엘지생명과학 | 혼합 백신의 제조 방법 |
-
1993
- 1993-05-15 EP EP97204034A patent/EP0835663B1/en not_active Revoked
- 1993-05-15 JP JP50016294A patent/JP3626996B2/ja not_active Expired - Lifetime
- 1993-05-15 DK DK93912750T patent/DK0642355T3/da active
- 1993-05-15 DE DE69319728T patent/DE69319728T2/de not_active Revoked
- 1993-05-15 AU AU43156/93A patent/AU4315693A/en not_active Abandoned
- 1993-05-15 CA CA002136429A patent/CA2136429C/en not_active Expired - Lifetime
- 1993-05-15 EP EP93912750A patent/EP0642355B1/en not_active Revoked
- 1993-05-15 CZ CZ942892A patent/CZ283910B6/cs not_active IP Right Cessation
- 1993-05-15 DE DE69334297T patent/DE69334297D1/de not_active Expired - Lifetime
- 1993-05-15 UA UA94129182A patent/UA40596C2/uk unknown
- 1993-05-15 DK DK97204034.9T patent/DK0835663T3/da active
- 1993-05-15 EP EP10179579A patent/EP2289548A3/en not_active Withdrawn
- 1993-05-15 SK SK1421-94A patent/SK280702B6/sk not_active IP Right Cessation
- 1993-05-15 PT PT97204034T patent/PT835663E/pt unknown
- 1993-05-15 SG SG1996009149A patent/SG48365A1/en unknown
- 1993-05-15 DE DE122010000016C patent/DE122010000016I1/de active Pending
- 1993-05-15 WO PCT/EP1993/001276 patent/WO1993024148A1/en not_active Application Discontinuation
- 1993-05-15 AT AT97204034T patent/ATE444079T1/de active
- 1993-05-15 AT AT93912750T patent/ATE168271T1/de not_active IP Right Cessation
- 1993-05-15 ES ES93912750T patent/ES2118963T3/es not_active Expired - Lifetime
- 1993-05-15 RU RU94046145/13A patent/RU2160120C2/ru active IP Right Maintenance
- 1993-05-15 ES ES97204034T patent/ES2334181T3/es not_active Expired - Lifetime
- 1993-05-15 NZ NZ253065A patent/NZ253065A/en not_active IP Right Cessation
- 1993-05-15 EP EP09171545A patent/EP2156845A1/en not_active Withdrawn
- 1993-05-15 DE DE122010000015C patent/DE122010000015I1/de active Pending
- 1993-05-15 KR KR1019940704215A patent/KR100287083B1/ko not_active IP Right Cessation
- 1993-05-15 HU HU9403366A patent/HU220236B/hu unknown
- 1993-05-20 MY MYPI93000939A patent/MY110665A/en unknown
- 1993-05-20 AP APAP/P/1993/000530A patent/AP567A/en active
- 1993-05-21 MA MA23192A patent/MA22894A1/fr unknown
- 1993-05-21 MX MX9302982A patent/MX9302982A/es active IP Right Grant
- 1993-05-21 SI SI9300271A patent/SI9300271A/sl not_active IP Right Cessation
- 1993-05-21 IL IL10577093A patent/IL105770A/en not_active IP Right Cessation
- 1993-05-22 CN CNB031332374A patent/CN1313152C/zh not_active Expired - Lifetime
- 1993-05-22 CN CNB931073197A patent/CN1136918C/zh not_active Ceased
-
1994
- 1994-11-22 NO NO944475A patent/NO309675B1/no not_active IP Right Cessation
- 1994-11-22 FI FI945483A patent/FI945483A/fi not_active Application Discontinuation
-
1996
- 1996-11-25 US US08/755,927 patent/US6013264A/en not_active Expired - Lifetime
-
1997
- 1997-03-24 AU AU16480/97A patent/AU709406C/en not_active Expired
-
1998
- 1998-11-30 HK HK98112444A patent/HK1011290A1/xx not_active IP Right Cessation
- 1998-11-30 HK HK00100138.3A patent/HK1021142A1/xx not_active IP Right Cessation
-
2002
- 2002-06-25 AU AU50629/02A patent/AU785433B2/en not_active Expired
-
2007
- 2007-03-16 AU AU2007201162A patent/AU2007201162A1/en not_active Abandoned
-
2010
- 2010-01-22 AU AU2010200249A patent/AU2010200249B2/en not_active Expired
- 2010-03-03 LU LU91659C patent/LU91659I2/fr unknown
- 2010-03-03 LU LU91658C patent/LU91658I2/fr unknown
-
2011
- 2011-03-02 CY CY1100003A patent/CY2614B2/xx unknown
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002506045A (ja) * | 1998-03-09 | 2002-02-26 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 併合ワクチン組成物 |
JP2002513771A (ja) * | 1998-05-01 | 2002-05-14 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | 新規組成物 |
JP2010209118A (ja) * | 1998-05-01 | 2010-09-24 | Glaxosmithkline Biologicals Sa | 新規組成物 |
JP2014028863A (ja) * | 1999-11-29 | 2014-02-13 | Novartis Vaccines & Diagnostics Srl | 血清型BおよびC由来のNeisseriameningitidis抗原、ならびにさらなる抗原を含む組成物 |
JP2008533125A (ja) * | 2005-03-17 | 2008-08-21 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | 全細胞百日咳抗原を含む混合ワクチン |
JP2012236864A (ja) * | 2006-08-16 | 2012-12-06 | Novartis Ag | 低減された抗原用量を有するブースターワクチンの製造 |
JP2015504085A (ja) * | 2012-01-17 | 2015-02-05 | サノフィ・パスツールSanofipasteur | 水酸化酸化アルミニウムへ吸着可能な少なくとも2種類の抗原を含有するワクチンの調製方法 |
JP2017203043A (ja) * | 2012-01-17 | 2017-11-16 | サノフィ パスツール エスエー | 水酸化酸化アルミニウムへ吸着可能な少なくとも2種類の抗原を含有するワクチンの調製方法 |
WO2022224966A1 (ja) * | 2021-04-20 | 2022-10-27 | Kmバイオロジクス株式会社 | 6種混合液状ワクチン組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07508267A (ja) | B型肝炎表面抗原および他の抗原からなる複合ワクチン | |
JP4653131B2 (ja) | 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン | |
EP2661277A2 (en) | A combination heptavalent vaccine | |
US20030157129A1 (en) | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein | |
US7144703B2 (en) | Composition | |
RU2287344C2 (ru) | Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека | |
AU2012202099A1 (en) | Combined vaccines comprising hepatitis B surface antigen and other antigens | |
MXPA97009732A (en) | Vaccine comprising a conjugate of antigen depolisacarido protein carrier and protein carrier li |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040224 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040412 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040602 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041012 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041111 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041111 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071217 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081217 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091217 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091217 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101217 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111217 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121217 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131217 Year of fee payment: 9 |
|
EXPY | Cancellation because of completion of term |